Kamila Duś-Szachniewicz1, Paweł Ostasiewicz2, Marta Woźniak2, Paweł Kołodziej2, Jacek R Wiśniewski3, Piotr Ziółkowski2. 1. Department of Pathology, Wrocław Medical University, Wrocław, Poland kamila.dus@gmail.com. 2. Department of Pathology, Wrocław Medical University, Wrocław, Poland. 3. Department of Proteomics and Signal Transduction, Biochemical Proteomics Group, Max Planck Institute of Biochemistry, Martinsried, Germany.
Abstract
BACKGROUND: Our previous liquid chromatography-tandem mass spectrometry (LC-MS/MS) study on colorectal cancer proteome resulted in identification of 10,000 differentially expressed proteins. We observed a significantly changed expression of 25% of all identified proteins between patient and matched adjacent normal mucosa, carcinoma and colorectal adenoma, including melanotransferrin. Herein, we consider this protein as a potential biomarker of colorectal cancer. MATERIALS AND METHODS: Immunohistochemical detection of melanotransferrin was carried-out to localize its expression pattern within the colorectal tissues by tissue microarray. The diagnostic utility of melanotransferrin was evaluated in patient serum by enzyme-linked immunosorbent assay (ELISA). RESULTS: Strong melanotransferrin expression was found to be related to clinicopathological characteristics, lymph node involvement (p=0.008), tumor localization in colon (p=0.001), presence of mucin (p<0.013) and increasing tumor grade (p<0.001). Melanotransferrin level in serum from patients with colorectal cancer was significantly higher than that in healthy controls (p<0.001). CONCLUSION: We provide novel evidence that melanotransferrin may be involved in transformation from benign tumor to malignancy and is a marker of an invasive tumor phenotype. Copyright
BACKGROUND: Our previous liquid chromatography-tandem mass spectrometry (LC-MS/MS) study on colorectal cancer proteome resulted in identification of 10,000 differentially expressed proteins. We observed a significantly changed expression of 25% of all identified proteins between patient and matched adjacent normal mucosa, carcinoma and colorectal adenoma, including melanotransferrin. Herein, we consider this protein as a potential biomarker of colorectal cancer. MATERIALS AND METHODS: Immunohistochemical detection of melanotransferrin was carried-out to localize its expression pattern within the colorectal tissues by tissue microarray. The diagnostic utility of melanotransferrin was evaluated in patient serum by enzyme-linked immunosorbent assay (ELISA). RESULTS: Strong melanotransferrin expression was found to be related to clinicopathological characteristics, lymph node involvement (p=0.008), tumor localization in colon (p=0.001), presence of mucin (p<0.013) and increasing tumor grade (p<0.001). Melanotransferrin level in serum from patients with colorectal cancer was significantly higher than that in healthy controls (p<0.001). CONCLUSION: We provide novel evidence that melanotransferrin may be involved in transformation from benign tumor to malignancy and is a marker of an invasive tumor phenotype. Copyright
Authors: Rikki A M Brown; Kirsty L Richardson; Tasnuva D Kabir; Debbie Trinder; Ruth Ganss; Peter J Leedman Journal: Front Oncol Date: 2020-04-09 Impact factor: 6.244
Authors: Michal Marczyk; Tao Qing; Tess O'Meara; Vesal Yagahoobi; Vasiliki Pelekanou; Yalai Bai; Emily Reisenbichler; Kimberly S Cole; Xiaotong Li; Vignesh Gunasekharan; Eiman Ibrahim; Kristina Fanucci; Wei Wei; David L Rimm; Lajos Pusztai; Kim R M Blenman Journal: NPJ Breast Cancer Date: 2022-07-22